Litigation Details for Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. (D. Del. 2021)

Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. (D. Del. 2021)

Docket		Date Filed	2021-12-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Mary Pat Thynge
Patents	9,439,906
Link to Docket	External link to docket

Details for Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-09-08	114	Order - Memorandum and Order AND ~Util - Terminate Motions	U.S. Patent No. 9,439,906 (“the ’906 patent”) against Tolmar in this action. The ’906 patent is generally…loading dose. ’906 patent, cl. 1. On its face, the ’906 patent claims priority to one …applicant for a patent.” Accordingly, the key question is whether the claims of the ’906 patent are entitled…AND ORDER In this Hatch-Waxman Act patent case, plaintiffs Janssen Pharmaceuticals Inc. and…dispute the priority date of the claims of the ’906 patent. For purposes of the present motion, claim	External link to document
2024-02-26	163	Findings of Fact & Conclusions of Law	Janssen is the owner of U.S. Patent No. 9,439,906 (“the ’906 patent”), entitled “Dosing Regimen…claimed in the patent, or the use of which is claimed in the patent, before the patent’s expiration.…pharmaceutical companies are protected by valid patents. If the patents are held to be infringed and not invalid… by generic manufacturers until the patents expire. If the patents are held to be invalid or not infringed…shall be an act of patent infringement to submit an ANDA for a drug claimed in a patent or the use of	External link to document